GeneDx Holdings Corp. (NASDAQ:WGS) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• GeneDx Holdings Corp. has received an average recommendation of "Moderate Buy" from eight research firms, with six analysts issuing buy ratings and two maintaining hold ratings.
• The average 1-year price target set by analysts for GeneDx is $101.63, with Guggenheim setting the highest target at $115.00.
• CFO Kevin Feeley and CEO Katherine Stueland recently sold significant shares of GeneDx, representing a decrease in their ownership positions; insiders sold a total of 561,641 shares valued at approximately $67.5 million in the last quarter.

Shares of GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $101.6250.

A number of research analysts have recently weighed in on WGS shares. Guggenheim reissued a "buy" rating and set a $115.00 target price (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wells Fargo & Company increased their target price on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research report on Friday, May 9th. Piper Sandler set a $120.00 target price on shares of GeneDx and gave the company an "overweight" rating in a research report on Monday, August 4th. Finally, Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd.

GeneDx Trading Up 1.8%

NASDAQ:WGS opened at $132.54 on Friday. GeneDx has a 52 week low of $31.22 and a 52 week high of $134.43. The firm has a 50-day moving average price of $104.18 and a two-hundred day moving average price of $91.10. The firm has a market cap of $3.81 billion, a price-to-earnings ratio of 2,650.80 and a beta of 2.04. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The firm had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, equities analysts expect that GeneDx will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling at GeneDx

In related news, CFO Kevin Feeley sold 5,278 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total value of $490,854.00. Following the completion of the transaction, the chief financial officer directly owned 3,392 shares of the company's stock, valued at approximately $315,456. This trade represents a 60.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 9,657 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $90.94, for a total transaction of $878,207.58. Following the completion of the transaction, the chief executive officer directly owned 4,940 shares of the company's stock, valued at approximately $449,243.60. This trade represents a 66.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 561,641 shares of company stock valued at $67,551,904 in the last quarter. Corporate insiders own 29.60% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Ameriprise Financial Inc. bought a new position in GeneDx in the 4th quarter valued at $2,645,000. Raymond James Financial Inc. boosted its holdings in GeneDx by 25.8% in the 1st quarter. Raymond James Financial Inc. now owns 333,376 shares of the company's stock valued at $29,525,000 after purchasing an additional 68,331 shares during the period. Voya Investment Management LLC bought a new position in GeneDx in the 4th quarter valued at $292,000. GAMMA Investing LLC raised its position in shares of GeneDx by 22,194.3% during the 1st quarter. GAMMA Investing LLC now owns 38,792 shares of the company's stock valued at $3,436,000 after buying an additional 38,618 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of GeneDx by 111.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 190,297 shares of the company's stock valued at $16,097,000 after buying an additional 100,146 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.